RiteStart Clinical Study Publication

8/1/2022
RiteStart Clinical Study Publication
Salt Lake City, UT (August 1, 2022) 4Life’s Research and Development scientists Lawry Han, PhD, FACN; Brent Vaughan, PhD, RD; and Chief Scientific Officer David Vollmer, PhD recently authored a peer-reviewed, clinical study in the Journal of Alternative Therapies.

The study explored the effects of RiteStart® Men and RiteStart® Women on important biomarkers in healthy men and women.

The introduction reads: “It is estimated that at least one-third of Americans take a multivitamin multimineral supplement (MVM) regularly. Though people might take an MVM for different reasons, studies have shown that its use improved not only nutrient intake, but also overall health. MVM use increases nutrient intake and helps people obtain their recommended intake of vitamins and minerals, especially when they cannot meet these needs from food alone.”

As published, the findings of this 12-week clinical study similarly determined that RiteStart has an excellent safety and tolerability profile. Among the significant findings: RiteStart supplementation improved serum levels of vitamin D, folate, and vitamin B12.

The study suggested an overall improvement in several areas, which findings should now be confirmed in a larger, placebo-controlled study.

Vice President of Product Development Dr. Han: “This study is another example of 4Life’s commitment to advancing transfer factor science and research. We will continue to study the structure-function benefits of 4Life products and publish whenever possible to remain a world leader.”

4Life, the Immune System Company®, and the first to bring transfer factor research to market, has offices in dozens of countries to serve the company’s worldwide customers.

For more information:
Calvin Jolley
Vice President Corporate Communications
4Life Research
[email protected]